The guidance provides information on review timelines during the COVID-19 pandemic.
FDA published guidance on Dec. 21, 2020 that gives information on the agency’s review timelines for applicant responses to complete response letters (CRL) when FDA must complete a facility assessment. The guidance applies to FDA review of amendments to original and supplemental abbreviated new drug applications (ANDAs) submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), resubmissions of original and supplemental biologics license applications (BLAs) submitted to FDA under sections 351(a) and (k) of the Public Health Service (PHS) Act, and resubmissions of original and supplemental new drug applications (NDAs) submitted under sections 505(b)(1) and (2) of the FD&C Act. The guidance and policy will remain in effect during the COVID-19 public health emergency.
In the guidance document, FDA explains how it will determine review timelines when a CRL is issued and a facility assessment is necessary before the agency can make a decision on an original or supplemental application. The guidance applies to manufacturing facilities and bioresearch monitoring program sites.
Timelines will not be changed for resubmissions of original applications, supplements with clinical data, and manufacturing supplements for BLAs under section 351(k) of the PHS Act,
regardless of whether FDA conducts an inspection or facility assessment. “Resubmitted manufacturing prior approval supplements will be subject to a four-month timeline. All other resubmitted applications and supplements in this category will be subject to a six-month timeline,” FDA noted in the guidance.
Resubmissions of manufacturing supplements for NDAs under sections 505(b)(1) and (2) of the FD&C Act and for BLAs under section 351(a) of the PHS Act will continue to be subject to existing user fee timelines.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.